Recursion Pharmaceuticals (RXRX) Cash from Operations (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted Cash from Operations of 81101000.0 for Q1 2026, down 76.03% on a QoQ basis from 46073000.0 in Q4 2025, and up 38.54% year-over-year from 58539844.85 in Q1 2025.
Recursion Pharmaceuticals (RXRX) Cash from Operations (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Cash from Operations history runs 7 years deep, the most recent figure standing at 81101000.0 for Q1 2026.
- Quarterly Cash from Operations rose 38.54% year-over-year to 81101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 320952000.0 (up 17.46% YoY) and the FY2025 annual result came in at 371808000.0, down 3.52% from the prior year.
- Cash from Operations was 81101000.0 for Q1 2026 at Recursion Pharmaceuticals, down from 46073000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 77388000.0 in Q1 2022 and bottomed at 131957000.0 in Q1 2025.
- A 5-year average of 69611000.0 and a median of 73316000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations jumped 351.63% — and 2023, when it tumbled 194.74%.
- Recursion Pharmaceuticals' Cash from Operations stood at 44748000.0 in 2022, then sank by 65.54% to 74077000.0 in 2023, then plunged by 55.82% to 115430000.0 in 2024, then jumped by 60.09% to 46073000.0 in 2025, then slumped by 76.03% to 81101000.0 in 2026.
- Business Quant data shows RXRX's Cash from Operations at 81101000.0 in Q1 2026, 46073000.0 in Q4 2025, and 117360000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -81.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.10 Mn |
| Mar 31, 2026 | -81.10 Mn |
| Dec 31, 2025 | -46.07 Mn |
| Dec 31, 2025 | -46.07 Mn |
| Sep 30, 2025 | -117.36 Mn |
| Sep 30, 2025 | -117.36 Mn |
| Jun 30, 2025 | -76.42 Mn |
| Jun 30, 2025 | -76.42 Mn |
| Mar 31, 2025 | -131.96 Mn |
| Mar 31, 2025 | -131.96 Mn |
| Dec 31, 2024 | -115.43 Mn |
| Dec 31, 2024 | -115.43 Mn |
| Sep 30, 2024 | -59.23 Mn |
| Sep 30, 2024 | -59.23 Mn |
| Jun 30, 2024 | -82.22 Mn |
| Jun 30, 2024 | -82.22 Mn |
| Mar 31, 2024 | -102.30 Mn |
| Mar 31, 2024 | -102.30 Mn |
| Dec 31, 2023 | -74.08 Mn |
| Dec 31, 2023 | -74.08 Mn |